Follow
Christopher McCabe
Christopher McCabe
Executive Director and CEO, Institute of Health Economics, Alberta
Verified email at ualberta.ca
Title
Cited by
Cited by
Year
ISPOR Task Force on Good Research Practices--Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task …
MC Weinstein, B O’Brien, J Hornberger, J Jackson, M Johannesson, ...
Value Health 6 (1), 9-17, 2003
1305*2003
The NICE cost-effectiveness threshold
C McCabe, K Claxton, AJ Culyer
Pharmacoeconomics 26 (9), 733-744, 2008
8102008
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
K Claxton, M Sculpher, C McCabe, A Briggs, R Akehurst, M Buxton, ...
Health economics 14 (4), 339-347, 2005
5052005
Whither trial‐based economic evaluation for health care decision making?
MJ Sculpher, K Claxton, M Drummond, C McCabe
Health economics 15 (7), 677-687, 2006
4332006
Patient volume, staffing, and workload in relation to risk-adjusted outcomes in a random stratified sample of UK neonatal intensive care units: a prospective evaluation
UK Neonatal Staffing Study Group
The Lancet 359 (9301), 99-107, 2002
3252002
Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
RJ Pollitt, A Green, CJ McCabe, A Booth, NJ Cooper, JV Leonard, ...
Health technology assessment (Winchester, England) 1 (7), i-iv, 1, 1997
3161997
Evaluation of a diabetic foot screening and protection programme
CJ McCabe, RC Stevenson, AM Dolan
Diabetic Medicine 15 (1), 80-84, 1998
3101998
An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative …
FJ Collinson, DG Jayne, A Pigazzi, C Tsang, JM Barrie, R Edlin, C Garbett, ...
International journal of colorectal disease 27 (2), 233-241, 2012
3072012
Measuring the mental health status of a population: A comparison of the GHQ–12 and the SF–36 (MHI–5)
CJ McCabe, KJ Thomas, JE Brazier, P Coleman
The British Journal of Psychiatry 169 (4), 517-521, 1996
2931996
Orphan drugs and the NHS: should we value rarity?
C McCabe, K Claxton, A Tsuchiya
Bmj 331 (7523), 1016-1019, 2005
2672005
Value based pricing for NHS drugs: an opportunity not to be missed?
K Claxton, A Briggs, MJ Buxton, AJ Culyer, C McCabe, S Walker, ...
Bmj 336 (7638), 251-254, 2008
2532008
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence
A Culyer, C McCabe, A Briggs, K Claxton, M Buxton, R Akehurst, ...
Journal of health services research & policy 12 (1), 56-58, 2007
2242007
Should patients have a greater role in valuing health states?
J Brazier, R Akehurst, A Brennan, P Dolan, K Claxton, C McCabe, ...
Applied health economics and health policy 4 (4), 201-208, 2005
1932005
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review
M Connock, A Burls, E Frew, A Fry-Smith, A Juarez-Garcia, C McCabe, ...
University of Leicester, 2006
1902006
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ...
The Lancet 393 (10191), 2599-2612, 2019
1862019
Plantar foot pressures during treadmill walking with high-heel and low-heel shoes
M Nyska, C McCabe, K Linge, L Klenerman
Foot & ankle international 17 (11), 662-666, 1996
1731996
Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines
GQ Daley, I Hyun, JF Apperley, RA Barker, N Benvenisty, AL Bredenoord, ...
Stem cell reports 6 (6), 787-797, 2016
1682016
Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others
J Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ...
JNCI: Journal of the National Cancer Institute 108 (9), 2016
1652016
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in …
J Chilcott, DH Miller, C McCabe, P Tappenden, A O'Hagan, NJ Cooper, ...
BMJ 326 (7388), 522, 2003
1632003
Funding the unfundable
T Stafinski, CJ McCabe, D Menon
Pharmacoeconomics 28 (2), 113-142, 2010
1562010
The system can't perform the operation now. Try again later.
Articles 1–20